CA2345767A1 - Therapie visant a ameliorer la cognition - Google Patents
Therapie visant a ameliorer la cognition Download PDFInfo
- Publication number
- CA2345767A1 CA2345767A1 CA002345767A CA2345767A CA2345767A1 CA 2345767 A1 CA2345767 A1 CA 2345767A1 CA 002345767 A CA002345767 A CA 002345767A CA 2345767 A CA2345767 A CA 2345767A CA 2345767 A1 CA2345767 A1 CA 2345767A1
- Authority
- CA
- Canada
- Prior art keywords
- atypical antipsychotic
- patients suffering
- acetylcholinesterase inhibitor
- alzheimer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000019771 cognition Effects 0.000 title claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 239000003693 atypical antipsychotic agent Substances 0.000 claims abstract description 23
- 239000000544 cholinesterase inhibitor Substances 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 19
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims abstract description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 206010012289 Dementia Diseases 0.000 claims abstract description 16
- 230000002411 adverse Effects 0.000 claims abstract description 13
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 10
- 230000009286 beneficial effect Effects 0.000 claims abstract description 8
- 230000001149 cognitive effect Effects 0.000 claims abstract description 4
- 230000006866 deterioration Effects 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000002195 synergetic effect Effects 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 229960003980 galantamine Drugs 0.000 claims description 9
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960001534 risperidone Drugs 0.000 claims description 8
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960003162 iloperidone Drugs 0.000 claims description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004431 quetiapine Drugs 0.000 claims description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 description 5
- -1 for example Chemical class 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Cette invention a trait à des compositions pharmaceutiques renfermant un excipient et, comme premier ingrédient actif, un agent antipsychotique atypique (I), ainsi que, comme second ingrédient actif, un inhibiteur de l'acétylcholinestérase (II), chacun sous des quantités produisant un effet thérapeutique bénéfique chez des patients atteints de psychose, de la maladie d'Alzheimer ou de démences connexes. Cet effet thérapeutique bénéfique peut être un effet de synergie sur le fonctionnement cognitif de patients atteints de la maladie d'Alzheimer ou de démences connexes, être prophylactique, évitant une dégradation ultérieure de la cognition chez ces patients, ou encore atténuant les réactions indésirables dues à l'action sur l'un des ingrédients actifs des autres ingrédients actifs.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454.8 | 1998-10-16 | ||
| EP98203454 | 1998-10-16 | ||
| PCT/EP1999/007804 WO2000023057A2 (fr) | 1998-10-16 | 1999-10-12 | Therapie visant a ameliorer la cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2345767A1 true CA2345767A1 (fr) | 2000-04-27 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002345767A Abandoned CA2345767A1 (fr) | 1998-10-16 | 1999-10-12 | Therapie visant a ameliorer la cognition |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (fr) |
| JP (1) | JP2002527469A (fr) |
| KR (1) | KR20010072878A (fr) |
| CN (1) | CN1367697A (fr) |
| AU (1) | AU6472799A (fr) |
| BG (1) | BG105302A (fr) |
| BR (1) | BR9914419A (fr) |
| CA (1) | CA2345767A1 (fr) |
| EE (1) | EE200100136A (fr) |
| HK (1) | HK1039745A1 (fr) |
| HR (1) | HRP20010262A2 (fr) |
| HU (1) | HUP0103781A3 (fr) |
| ID (1) | ID28441A (fr) |
| IL (1) | IL142588A0 (fr) |
| NO (1) | NO20011403L (fr) |
| PL (1) | PL348107A1 (fr) |
| SK (1) | SK4592001A3 (fr) |
| TR (1) | TR200101082T2 (fr) |
| WO (1) | WO2000023057A2 (fr) |
| ZA (1) | ZA200103081B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| CA2463158C (fr) * | 2001-10-30 | 2013-07-30 | Novartis Ag | Preparations de depot d'iloperidone et de polymere en etoile |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2006065233A1 (fr) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Dérivés polycycliques de quinuclidine substitués par un bicyclohétérocycle condensé |
| US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
| WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
| EP2091948B1 (fr) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Nouveaux inhibiteurs de glutaminylcyclase |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| WO2011107530A2 (fr) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Nouveaux inhibiteurs |
| CA2789440C (fr) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Inhibiteurs heterocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| AU2016268096B2 (en) | 2015-05-22 | 2021-04-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3461819B1 (fr) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibiteurs de la glutaminyl-cyclase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992020327A1 (fr) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| CA2300148C (fr) * | 1997-08-11 | 2009-06-23 | University Of South Florida | Antagonistes de la nicotine destines a des troubles neuropsychiatriques sensibles a la nicotine |
| CA2328197C (fr) * | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methodes de traitement de troubles neuropsychiatriques |
-
1999
- 1999-10-12 HK HK02100158.6A patent/HK1039745A1/zh unknown
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Withdrawn
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 CA CA002345767A patent/CA2345767A1/fr not_active Abandoned
- 1999-10-12 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 1999-10-12 EP EP99952580A patent/EP1121131A2/fr not_active Withdrawn
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/fr not_active Ceased
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6472799A (en) | 2000-05-08 |
| KR20010072878A (ko) | 2001-07-31 |
| HUP0103781A2 (hu) | 2002-03-28 |
| WO2000023057A3 (fr) | 2000-07-27 |
| EP1121131A2 (fr) | 2001-08-08 |
| ZA200103081B (en) | 2002-07-12 |
| HK1039745A1 (zh) | 2002-05-10 |
| HUP0103781A3 (en) | 2003-09-29 |
| IL142588A0 (en) | 2002-03-10 |
| NO20011403D0 (no) | 2001-03-20 |
| PL348107A1 (en) | 2002-05-06 |
| WO2000023057A2 (fr) | 2000-04-27 |
| SK4592001A3 (en) | 2001-12-03 |
| BG105302A (en) | 2001-11-30 |
| ID28441A (id) | 2001-05-24 |
| EE200100136A (et) | 2002-06-17 |
| TR200101082T2 (tr) | 2001-09-21 |
| BR9914419A (pt) | 2001-06-26 |
| JP2002527469A (ja) | 2002-08-27 |
| CN1367697A (zh) | 2002-09-04 |
| NO20011403L (no) | 2001-03-20 |
| HRP20010262A2 (en) | 2002-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2345767A1 (fr) | Therapie visant a ameliorer la cognition | |
| RU2212886C2 (ru) | КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ И ПРЕДОТВРАЩЕНИЯ АРТЕРИАЛЬНОГО ТРОМБОЗА И ПРИМЕНЕНИЕ ИНГИБИТОРА ФАКТОРА Ха САМОГО ПО СЕБЕ И/ИЛИ В КОМБИНАЦИИ С АГЕНТОМ, ПРЕПЯТСТВУЮЩИМ АГРЕГАЦИИ ТРОМБОЦИТОВ | |
| RU93004484A (ru) | Производные пиразола, способ их получения и содержащие их фармацевтические композиции | |
| US6291471B1 (en) | Use of apomorphine for the treatment of organic erectile dysfunction in males | |
| YU66600A (sh) | Farmaceutski preparati koji mogu da budu gelirani | |
| IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
| JP2001523715A (ja) | 脂肪酸のコリンエステル及び脳卒中の治療におけるそれらの使用 | |
| JP2019510039A5 (fr) | ||
| MD1699F2 (ro) | Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei | |
| ATE224712T1 (de) | Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen | |
| CA2433585A1 (fr) | Compositions pharmaceutiques contenant du chlorhydrate de donepezil | |
| JPWO2000064478A1 (ja) | 肝臓疾患の予防治療薬 | |
| CA2378613A1 (fr) | Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine | |
| CN1317030C (zh) | 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 | |
| JP4135263B2 (ja) | クリーム状洗浄剤組成物 | |
| JPH04217915A (ja) | ４−エチル−２−ヒドロキシイミノ−５−ニトロ−３−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| JP2004123558A (ja) | 片頭痛の予防、治療剤 | |
| CA1209047A (fr) | Compose therapeutique contenant un analogue du piracetam | |
| CA2590224A1 (fr) | Procede pour la reduction, la stabilisation et la prevention de la rupture d'une plaque riche en lipides | |
| MXPA02012957A (es) | Formulacion nueva. | |
| NZ321370A (en) | Polymorphic forms of a growth hormone secretagogue | |
| EP0671908A1 (fr) | Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht 1? et des stimulateurs d'absorption | |
| RU2001113270A (ru) | Лечение, направленное на улучшение познавательной способности | |
| HU9904440D0 (en) | Pharmaceutical composition for the prevention and the treatment of fungus-infected and process producing the agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |